SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Hiroshi Yoneyama, Asako Takizawa-Hashimoto, Osamu Takeuchi, Yukiko Watanabe, Koichiro Atsuda, Fumiki Asanuma, Yoshinori Yamada, Yukio Suzuki, Acquired resistance to gemcitabine and cross-resistance in human pancreatic cancer clones, Anti-Cancer Drugs, 2015, 26, 1, 90

    CrossRef

  2. 2
    Sebastiano Buti, Chiara Ciccarese, Daniele Zanoni, Matteo Santoni, Alessandra Modena, Francesca Maines, Annalisa Gilli, Emilio Bria, Matteo Brunelli, Anita Rimanti, Stefano Cascinu, Andrea Ardizzoni, Giampaolo Tortora, Francesco Massari, Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?, Future Oncology, 2015, 11, 1, 107

    CrossRef

  3. 3
    Fenglei Wu, Jian Zhang, Nan Hu, Huiyu Wang, Tongpeng Xu, Yi Liu, Yitong Zheng, Effect of hENT1 polymorphism G-706C on clinical outcomes of gemcitabine-containing chemotherapy for Chinese non-small-cell lung cancer patients, Cancer Epidemiology, 2014, 38, 6, 728

    CrossRef

  4. 4
    Yingzhe Wang, Wei Fan, Xin Dai, Usha Katragadda, DeAngelo Mckinley, Quincy Teng, Chalet Tan, Enhanced Tumor Delivery of Gemcitabine via PEG-DSPE/TPGS Mixed Micelles, Molecular Pharmaceutics, 2014, 11, 4, 1140

    CrossRef

  5. 5
    Maria L. Alvarellos, Jatinder Lamba, Katrin Sangkuhl, Caroline F. Thorn, Liewei Wang, Daniel J. Klein, Russ B. Altman, Teri E. Klein, PharmGKB summary, Pharmacogenetics and Genomics, 2014, 24, 11, 564

    CrossRef

  6. 6
    Raphaël Maréchal, Anne Demols, Jean-Luc Van Laethem, Adjuvant Pharmacotherapy in the Management of Elderly Patients with Pancreatic Cancer, Drugs & Aging, 2013, 30, 3, 155

    CrossRef

  7. 7
    Jia–Jia Wu, Shun–Chang Jiao, Expression of hENTl and ERCC1 genes in tumor tissues non-small cell lung cancer, Asian Pacific Journal of Tropical Medicine, 2013, 6, 11, 908

    CrossRef

  8. 8
    Ken Ohmine, Kei Kawaguchi, Sumio Ohtsuki, Fuyuhiko Motoi, Shinichi Egawa, Michiaki Unno, Tetsuya Terasaki, Attenuation of Phosphorylation by Deoxycytidine Kinase is Key to Acquired Gemcitabine Resistance in a Pancreatic Cancer Cell Line: Targeted Proteomic and Metabolomic Analyses in PK9 Cells, Pharmaceutical Research, 2012, 29, 7, 2006

    CrossRef

  9. 9
    Hye In Woo, Ka-Kyung Kim, Hangseok Choi, Seonwoo Kim, Kee-Taek Jang, Jun Ho Yi, Young Suk Park, Joon Oh Park, Soo-Youn Lee, Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine, Pharmacogenomics, 2012, 13, 9, 1023

    CrossRef

  10. 10
    Raphaël Maréchal, Jean–Baptiste Bachet, John R. Mackey, Cécile Dalban, Pieter Demetter, Kathryn Graham, Anne Couvelard, Magali Svrcek, Armelle Bardier–Dupas, Pascal Hammel, Alain Sauvanet, Christophe Louvet, François Paye, Philippe Rougier, Christophe Penna, Thierry André, Charles Dumontet, Carol E. Cass, Lars Petter Jordheim, Eva–Laure Matera, Jean Closset, Isabelle Salmon, Jacques Devière, Jean–François Emile, Jean–Luc Van Laethem, Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma, Gastroenterology, 2012, 143, 3, 664

    CrossRef

  11. 11
    Jules Lin, David G. Beer, Molecular Predictors of Prognosis in Lung Cancer, Annals of Surgical Oncology, 2012, 19, 2, 669

    CrossRef

  12. 12
    Elisa Giovannetti, Francesca Toffalorio, Tommaso De Pas, Godefridus J Peters, Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?, Pharmacogenomics, 2012, 13, 9, 1073

    CrossRef

  13. 13
    Trinidad D. Montero, Dusan Racordon, Loreto Bravo, Gareth I. Owen, Miguel L. Bronfman, Andrea V. Leisewitz, PPARα and PPARγ regulate the nucleoside transporter hENT1, Biochemical and Biophysical Research Communications, 2012, 419, 2, 405

    CrossRef

  14. 14
    Nina Erčulj, Viljem Kovač, Julija Hmeljak, Alenka Franko, Metoda Dodič-Fikfak, Vita Dolžan, The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma, Pharmacogenetics and Genomics, 2012, 22, 1, 58

    CrossRef

  15. 15
    Min-Koo Choi, Variability of gemcitabine accumulation and its relationship to expression of nucleoside transporters in peripheral blood mononuclear cells, Archives of Pharmacal Research, 2012, 35, 5, 921

    CrossRef

  16. You have free access to this content16
    Milena Gusella, Felice Pasini, Caterina Bolzonella, Silvia Meneghetti, Carmen Barile, Antonio Bononi, Silvia Toso, Daniela Menon, Giorgio Crepaldi, Yasmina Modena, Laura Stievano, Roberto Padrini, Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours, British Journal of Clinical Pharmacology, 2011, 71, 3
  17. 17
    Jun Sato, Takashi Kimura, Takuro Saito, Takayuki Anazawa, Akira Kenjo, Yoshihiro Sato, Takao Tsuchiya, Mitsukazu Gotoh, Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma, Journal of Hepato-Biliary-Pancreatic Sciences, 2011, 18, 5
  18. 18
    Min-Kyoung Kim, Yoon-Kyung Jeon, Jong-Kyu Woo, Yun Choi, Dae-Han Choi, Yeul-Hong Kim, Chul-Woo Kim, The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1, Molecular Cancer, 2011, 10, 1, 98

    CrossRef

  19. 19
    F Toffalorio, E Giovannetti, T De Pas, D Radice, G Pelosi, M Manzotti, D Minocci, L Spaggiari, G Spitaleri, C Noberasco, C Catania, S Boselli, R Danesi, F de Braud, Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer, The Pharmacogenomics Journal, 2010, 10, 3, 180

    CrossRef

  20. 20
    Gabriella Ferrandina, Valentina Mey, Sara Nannizzi, Simona Ricciardi, Marco Petrillo, Cristiano Ferlini, Romano Danesi, Giovanni Scambia, Mario Del Tacca, Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer, Cancer Chemotherapy and Pharmacology, 2010, 65, 4, 679

    CrossRef

  21. 21
    Motofumi Tanaka, Milind Javle, Xiaoqun Dong, Cathy Eng, James L. Abbruzzese, Donghui Li, Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer, Cancer, 2010, 116, 22
  22. 22
    Luca Toschi, Federico Cappuzzo, Impact of biomarkers on non-small cell lung cancer treatment, Targeted Oncology, 2010, 5, 1, 5

    CrossRef

  23. 23
    M. Candelaria, E. de la Cruz-Hernández, E. Pérez-Cárdenas, C. Trejo-Becerril, O. Gutiérrez-Hernández, A. Dueñas-González, Pharmacogenetics and pharmacoepigenetics of gemcitabine, Medical Oncology, 2010, 27, 4, 1133

    CrossRef

  24. 24
    Paola Gazzaniga, Angela Gradilone, Ettore De Berardinis, Alessandro Sciarra, Cristiano Cristini, Giuseppe Naso, Franco Di Silverio, Luigi Frati, Anna Maria Aglianò, A chemosensitivity test to individualize intravesical treatment for non-muscle-invasive bladder cancer, BJU International, 2009, 104, 2
  25. 25
    James J. Farrell, Hany Elsaleh, Miguel Garcia, Raymond Lai, Ali Ammar, William F. Regine, Ross Abrams, A. Bowen Benson, John Macdonald, Carol E. Cass, Adam P. Dicker, John R. Mackey, Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer, Gastroenterology, 2009, 136, 1, 187

    CrossRef

  26. 26
    Vijaya L. Damaraju, Michael B. Sawyer, John R. Mackey, James D. Young, Carol E. Cass, Human Nucleoside Transporters: Biomarkers for Response to Nucleoside Drugs, Nucleosides, Nucleotides and Nucleic Acids, 2009, 28, 5-7, 450

    CrossRef

  27. 27
    Romano Danesi, Giuseppe Pasqualetti, Elisa Giovannetti, Francesco Crea, Giuseppe Altavilla, Mario Del Tacca, Rafael Rosell, Pharmacogenomics in non-small-cell lung cancer chemotherapy, Advanced Drug Delivery Reviews, 2009, 61, 5, 408

    CrossRef

  28. 28
    Romano Danesi, Giuseppe Altavilla, Elisa Giovannetti, Raffael Rosell, Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors, Pharmacogenomics, 2009, 10, 1, 69

    CrossRef

  29. 29
    Sandra Pérez-Torras, José García-Manteiga, Elena Mercadé, F. Javier Casado, Neus Carbó, Marçal Pastor-Anglada, Adela Mazo, Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer, Biochemical Pharmacology, 2008, 76, 3, 322

    CrossRef

  30. 30
    I. Hubeek, E. Giovannetti, A. J. F. Broekhuizen, M. Pastor-Anglada, G. J. L. Kaspers, G. J. Peters, Immunocytochemical Detection of hENT1 and hCNT1 in Normal Tissues, Lung Cancer Cell Lines, and NSCLC Patient Samples, Nucleosides, Nucleotides and Nucleic Acids, 2008, 27, 6-7, 787

    CrossRef

  31. 31
    Niccola Funel, Elisa Giovannetti, Marco Del Chiaro, Valentina Mey, Luca E Pollina, Sara Nannizzi, Ugo Boggi, Simona Ricciardi, Mario Del Tacca, Generoso Bevilacqua, Franco Mosca, Romano Danesi, Daniela Campani, Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma, Laboratory Investigation, 2008, 88, 7, 773

    CrossRef

  32. 32
    Lakkireddy Harivardhan Reddy, Humberto Ferreira, Catherine Dubernet, Sinda Lepetre Mouelhi, Didier Desmaele, Bernard Rousseau, Patrick Couvreur, Squalenoyl nanomedicine of gemcitabine is more potent after oral administration in leukemia-bearing rats: study of mechanisms, Anti-Cancer Drugs, 2008, 19, 10, 999

    CrossRef

  33. 33
    Su-Ryang KIM, Yoshiro SAITO, Keiko MAEKAWA, Emiko SUGIYAMA, Nahoko KANIWA, Hideki UENO, Takuji OKUSAKA, Masafumi IKEDA, Chigusa MORIZANE, Noboru YAMAMOTO, Teruhiko YOSHIDA, Naoyuki KAMATANI, Junji FURUSE, Hiroshi ISHII, Nagahiro SAIJO, Shogo OZAWA, Jun-ichi SAWADA, Twenty Novel Genetic Variations and Haplotype Structures of the DCK Gene Encoding Human Deoxycytidine Kinase (dCK), Drug Metabolism and Pharmacokinetics, 2008, 23, 5, 379

    CrossRef

  34. 34
    Xiyong Liu, Bingsen Zhou, Shu Mi, Lijun Xue, Jennifer Shih, Janice Lee, Jennifer Chau, Frank Un, Yun Yen, An increase of cytochrome C oxidase mediated disruption of gemcitabine incorporation into DNA in a resistant KB clone, Biochemical Pharmacology, 2007, 73, 12, 1927

    CrossRef

  35. 35
    Yoshio Endo, Tohru Obata, Daigo Murata, Mariho Ito, Kazuki Sakamoto, Masakazu Fukushima, Yasundo Yamasaki, Yuji Yamada, Nagato Natsume, Takuma Sasaki, Cellular localization and functional characterization of the equilibrative nucleoside transporters of antitumor nucleosides, Cancer Science, 2007, 98, 10
  36. 36
    Luca Toschi, Giovanna Finocchiaro, Giovanni Luca Ceresoli, Paolo Andrea Zucali, Raffaele Cavina, Isabella Garassino, Fabio De Vincenzo, Armando Santoro, Federico Cappuzzo, Is gemcitabine cost effective in cancer treatment?, Expert Review of Pharmacoeconomics & Outcomes Research, 2007, 7, 3, 239

    CrossRef

  37. 37
    Mark N. Kirstein, Katie M. Wieman, Brent W. Williams, James E. Fisher, Paul H. Marker, Chap T. Le, Douglas Yee, Robert A. Kratzke, Short versus continuous gemcitabine treatment of non-small cell lung cancer in an in vitro cell culture bioreactor system, Lung Cancer, 2007, 58, 2, 196

    CrossRef

  38. 38
    Tetsuya Oguri, Hiroyuki Achiwa, Hideki Muramatsu, Hiroaki Ozasa, Shigeki Sato, Shigeki Shimizu, Hideko Yamazaki, Tadaaki Eimoto, Ryuzo Ueda, The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer, Cancer Letters, 2007, 256, 1, 112

    CrossRef

  39. 39
    Jing Zhang, Frank Visser, Karen M. King, Stephen A. Baldwin, James D. Young, Carol E. Cass, The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs, Cancer and Metastasis Reviews, 2007, 26, 1, 85

    CrossRef

  40. 40
    Romano Danesi, Giuseppe Pasqualetti, Elisa Giovannetti, Mario Del Tacca, The Role of Pharmacogenetics in Adjuvant Treatment of Non-small Cell Lung Cancer, Journal of Thoracic Oncology, 2007, 2, Supplement 1, S27

    CrossRef

  41. 41
    V Mey, E Giovannetti, F De Braud, S Nannizzi, G Curigliano, F Verweij, O De Cobelli, S Pece, M Del Tacca, R Danesi, In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients, British Journal of Cancer, 2006, 95, 3, 289

    CrossRef

  42. 42
    Paul Chen, Pei-Yu Chien, Abdul R. Khan, Saifuddin Sheikh, Shoukath M. Ali, Moghis U. Ahmad, Imran Ahmad, In-vitro and in-vivo anti-cancer activity of a novel gemcitabine???cardiolipin conjugate, Anti-Cancer Drugs, 2006, 17, 1, 53

    CrossRef

  43. 43
    R. Rosell, T. Moran, M. Fernanda Salazar, P. Mendez, I. De Aguirre, J.-L. Ramirez, D. Isla, M. Cobo, C. Camps, G. Lopez-Vivanco, V. Alberola, M. Taron, The place of targeted therapies in the management of non-small cell bronchial carcinoma, Revue des Maladies Respiratoires, 2006, 23, 5, 131

    CrossRef

  44. 44
    Su-Ryang KIM, Yoshiro SAITO, Keiko MAEKAWA, Emiko SUGIYAMA, Nahoko KANIWA, Hideki UENO, Takuji OKUSAKA, Chigusa MORIZANE, Noboru YAMAMOTO, Masafumi IKEDA, Teruhiko YOSHIDA, Hironobu MINAMI, Junji FURUSE, Hiroshi ISHII, Nagahiro SAIJO, Naoyuki KAMATANI, Shogo OZAWA, Jun-ichi SAWADA, Thirty Novel Genetic Variations in the SLC29A1 Gene Encoding Human Equilibrative Nucleoside Transporter 1 (hENT1), Drug Metabolism and Pharmacokinetics, 2006, 21, 3, 248

    CrossRef

  45. 45
    Rafael Rosell, Mauricio Cuello, Fabiana Cecere, Mariacarmela Santarpia, Noemi Reguart, Enriqueta Felip, Miquel Taron, Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going, Current Opinion in Oncology, 2006, 18, 2, 135

    CrossRef

  46. 46
    Sharon K. Wu, Neil R. Mathias, Kwang-Jin Kim, Vincent H.L. Lee, Functional and pharmacological mechanisms of nucleoside transport across the basolateral membrane of rabbit tracheal epithelial cells, Life Sciences, 2005, 78, 3, 310

    CrossRef

  47. 47
    Volker Heinemann, Gemcitabine in metastatic breast cancer, Expert Review of Anticancer Therapy, 2005, 5, 3, 429

    CrossRef

  48. 48
    Hiromi Kazuno, Kazuki Sakamoto, Akio Fujioka, Masakazu Fukushima, Akira Matsuda, Takuma Sasaki, Possible antitumor activity of 1-(3-C-ethynyl-β-d-ribo-pentofuranosyl)cytosine (ECyd, TAS-106) against an established gemcitabine (dFdCyd)-resistant human pancreatic cancer cell line, Cancer Science, 2005, 96, 5
  49. 49
    Jennifer Sigmond, Godefridus J. Peters, Pyrimidine and Purine Analogues, Effects on Cell Cycle Regulation and the Role of Cell Cycle Inhibitors to Enhance Their Cytotoxicity, Nucleosides, Nucleotides and Nucleic Acids, 2005, 24, 10-12, 1997

    CrossRef

  50. 50
    L Toschi, G Finocchiaro, S Bartolini, V Gioia, F Cappuzzo, Role of gemcitabine in cancer therapy, Future Oncology, 2005, 1, 1, 7

    CrossRef

  51. 51
    Tetsuya Oguri, Hiroyuki Achiwa, Yuji Bessho, Hideki Muramatsu, Hiroyoshi Maeda, Takashi Niimi, Shigeki Sato, Ryuzo Ueda, The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells, Lung Cancer, 2005, 49, 3, 345

    CrossRef